← Leaderboards
Jonathan David Mosley
Vanderbilt University Medical Center
$3,613,133
Attributed
$4,970,478
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–23$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,970,478 · 2
By mechanism
R01$4,970,478 · 2
Top collaborators
- Jane F Ferguson5 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Wei-Qi Wei$9,737,275
- Dan M Roden$145,793,078
- Lisa Bastarache$6,344,381
- Jane F Ferguson$4,116,241
- Vern Eric Kerchberger$844,964
Others in their field
Other Emerging Leaders on “Target Populations”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Leonard Freedman · Leidos Biomedical Research, Inc.$34,953,667
- Timothy M Willson · University Of Cape Town$32,741,597
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
Research focus
Target PopulationsPredictive MarkerResearch DesignSingle Nucleotide PolymorphismMorbidity - Disease RatePhenomeCostElectronic Medical Records And Genomics NetworkInnovationHeritabilityLinkMeasurementBiological MarkersPathologicClinical DiagnosisClinically RelevantElectronic Health RecordDisorder RiskCardiacGeneticGenetic PredictorsGenome Wide Association StudyBiobankBase
Grant awards (10)
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology$542,938
R01 · FY2023 · HL
Leveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkers$365,803
R01 · FY2023 · GM · contact PI
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology$542,938
R01 · FY2022 · HL
Leveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkers$365,803
R01 · FY2022 · GM · contact PI
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology$542,938
R01 · FY2021 · HL
Leveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkers$365,803
R01 · FY2021 · GM · contact PI
Leveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkers$562,329
R01 · FY2020 · GM · contact PI
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology$542,938
R01 · FY2020 · HL
Leveraging common genetic variation to reduce misclassification of non-diseased individuals and unnecessary health care utilization attributable to surrogate biomarkers$596,050
R01 · FY2019 · GM · contact PI
Virtual metabolomics as a discovery tool for novel cardiometabolic disease biology$542,938
R01 · FY2019 · HL